Clinical Trial Search

Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants

Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635

Primary: Diagnosis of Pneumonia — 40; 32; 4; 12 Participants

Primary: Use of Antibiotics in Each Group — 28; 52 participants

Primary: The Primary Endpoint is the Occurrence of Dose Limiting Toxicity (DLT). — 0; 0 participants

Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024

Primary: Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28 — 24.0; 25.3 Percentage of Participants

Primary: All-cause Mortality Rate at Day 14 — 12.4; 11.6 percentage of participants — p=0.0020

Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants

Primary: Adverse Events — 10; 5; 1; 0 Participants

Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants

Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01

Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts

Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts

Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale